

frequent mitotic figures. On immunohistochemistry, the cells are positive for CD117, vimentin and BCL2. Wnt-APC beta-catenin pathway is implicated in the pathogenesis of these tumours with 72% of cases in a study showing stromal nuclear staining by beta-catenin [3]. They are usually benign and only few of them undergo malignant transformation and p53 gene mutation is the most common abnormality seen in this condition. Stromal p53 expression has almost consistently been reported to increase significantly with phyllodes tumour grade [4]. In a study frequent gain of 1q, deletion/copy-neutral LOH in chromosome 13 along with +7p and -9p were found in in borderline and malignant tumors using array CGH. The study found that in the borderline/malignant cases with 9p deletion, the deletion localized to 9p21.3, the site of p16INK4a [5]. Figure 1 shows a summation of the correlations of immunohistochemical/genetic changes in the progression of phyllodes tumors [5].




Fig 1

REFERENCES

1. B. Erginel, B. Celet Ozden, S. Yesil Onder, S. Yuksel, F. Gun Soysal, A. Celik, et al. Management of a benign phyllodes tumor in a 13-year old girl with trans-position of the nipple areola complex and breast reconstruction. *Acta Chir Belg*, 115 (3) (2015 May–Jun), pp. 256–259
2. WHO Classification of Tumours, Volume 4 IARC WHO Classification of Tumours, No 4 Lakhani, S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J. IARC
3. Sawyer EJ, Hanby AM, Rowan AJ, Gillett CE, Thomas RE, Poulson R, Lakhani SR, Ellis IO, Ellis P, Tomlinson IP. The Wnt pathway, epithelial stromal interactions, and malignant progression in phyllodes tumors. *J Pathol*. 2002;196:437–44.
4. Tse GM, Tan PH. Recent advances in the pathology of fibroepithelial tumors of the breast. *Curr Diagn Pathol*. 2005;11:426–434.
5. Jones AM, Springall R, Graham T, Winter E, Gillett C, Hanby AM, The Phyllodes Tumour Consortium. Tomlinson IPM, Sawyer EJ. A comprehensive genetic profile of phyllodes tumors of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. *J Pathol*. 2008;214:533–544.